Who is sponsoring NCT06045286?

NCT06045286 is sponsored by Jiangsu Cancer Institute & Hospital.

What drugs are being tested in NCT06045286?

Interventions in NCT06045286: Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors.

What condition does NCT06045286 study?

NCT06045286 studies Colorectal Liver Metastases.

Is NCT06045286 still recruiting?

NCT06045286 is currently status unknown. Last updated 21 September 2023.

Last reviewed 2023-09-21 · How we verify

NCT06045286: HaRyPOT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM

Status unknown Phase 1 Last updated 21 September 2023

What this trial tests

Phase 1 trial testing Radiation: High- and Low-dose radiotherapy in Colorectal Liver Metastases in 30 participants. Status unknown.

Timeline

20 September 2023

Primary endpoint
30 September 2024

31 December 2025

Quick facts

Lead sponsor	Jiangsu Cancer Institute & Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	20 September 2023
Primary completion	30 September 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Radiation: High- and Low-dose radiotherapy
PD-1 Inhibitors — full drug profile →

Conditions studied

Colorectal Liver Metastases — all drugs for Colorectal Liver Metastases →

Sponsor

Jiangsu Cancer Institute & Hospital

Who can join

18 and older, any sex, with Colorectal Liver Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot phase I trial aims to investigate the efficacy and safety of high- and low-dose radiotherapy combined with programmed cell death-1 (PD-1) inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that have failed second-line immunotherapy or above.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment.
Liu Y, Yang H, Li T, Zhang N. · · 2024 · cited 23× · PMID 39295859 · DOI 10.3389/fimmu.2024.1460282
Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.
Li K, Guo B, Gu J, Ta N, et al · · 2025 · cited 8× · PMID 39759851 · DOI 10.1016/j.mtbio.2024.101375
Liver Extracellular Matrix in Colorectal Liver Metastasis.
Morabito M, Thibodot P, Gigandet A, Compagnon P, et al · · 2025 · cited 4× · PMID 40149289 · DOI 10.3390/cancers17060953
Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases.
Cives-Losada C, Soldani C, Polidoro MA, Franceschini B, et al · · 2026 · PMID 41930154 · DOI 10.32604/or.2025.074093
RT-ICI therapy induces a distal immunometabolic axis that shapes systemic macrophage polarization and enhances local T cell immunity.
Ge Y, Liu H, Shen J, Xu H, et al · · 2026 · PMID 41654947 · DOI 10.1186/s12964-026-02689-3
High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT).
Ding Y, Feng Y, Ye Y, Shen J, et al · · 2025 · PMID 39980556 · DOI 10.3389/fonc.2025.1503517

Verify or expand the search:

Other recruiting trials for Colorectal Liver Metastases

Currently open trials in the same condition.

NCT06501482 — Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI · Phase 3 · recruiting
NCT07117435 — Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in · Phase 1 · recruiting
NCT06638502 — Safety of HRX215 in Patients After Minor and Major Liver Resection · Phase 1, PHASE2 · recruiting
NCT05265169 — Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) · NA · recruiting

Other Jiangsu Cancer Institute & Hospital trials

Trials by the same sponsor.

NCT07408609 — Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal · Phase 2 · not yet recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT07446387 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regim · Phase 2 · not yet recruiting
NCT07311577 — Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD- · Phase 2 · recruiting
NCT05912582 — Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06045286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Cancer Institute & Hospital
Last refreshed: 21 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06045286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing